Current Document Type: HighlightsVideoPage Treatment of CLL/SLL: 7-Year Follow-up Data - JADPRO

Watch More Highlights

Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses phase Ib/II study findings on single-agent ibrutinib in the first-line and relapsed or refractory settings for chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 3133).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.